Enrolling by invitation

Berberine's Effects on Lipids and Lipoproteins in Hyperlipidemic Chinese Women

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Berberine

+ Placebo

Drug
Who is being recruted

Hyperlipidemias+2

+ Metabolic Diseases

+ Nutritional and Metabolic Diseases

From 20 to 65 Years
See all eligibility criteria
How is the trial designed

Prevention Study

Placebo-ControlledPhase 2 & 3
Interventional
Study Start: August 2024
See protocol details

Summary

Principal SponsorThe University of Hong Kong
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: August 1, 2024

Actual date on which the first participant was enrolled.

This study aims to explore how the supplement berberine affects cholesterol levels and certain proteins related to cholesterol in the body, with a focus on potential differences between men and women. The study targets Chinese women in Hong Kong who have high cholesterol levels, also known as hyperlipidemia. Researchers are particularly interested in understanding if berberine can improve levels of total cholesterol, LDL, HDL, and triglycerides, among other factors, and if these effects vary between sexes. This research is important because finding effective treatments for high cholesterol can help prevent heart disease and other related health issues. Participants in the study will be divided into two groups. One group will receive berberine, while the other will receive a placebo, which is a harmless pill with no active ingredients. Both groups will take their assigned treatment twice a day for 12 weeks. Blood samples will be collected at the start, after 8 weeks, and again at the end of the 12-week period to measure changes in cholesterol and related proteins. The study will use a method called intention-to-treat analysis to ensure that the results are comprehensive and reliable, analyzing the effects of berberine across the entire period.

Official TitleAssessing the Sex-specific, Lipid- and Lipoprotein-lowering Effects of Berberine Using Randomized, Placebo-controlled, Double-masked Trial
NCT06782646
Principal SponsorThe University of Hong Kong
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

100 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Prevention Study

Prevention studies aim to stop a disease from developing. They often involve people at risk and test things like vaccines, lifestyle changes, or preventive medications.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Female

Biological sex of participants that are eligible to enroll.

From 20 to 65 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

HyperlipidemiasMetabolic DiseasesNutritional and Metabolic DiseasesDyslipidemiasLipid Metabolism Disorders

Criteria

Inclusion Criteria: * Women, who are: 1. aged 20 to 65 years. 2. of Chinese ethnicity. 3. with hyperlipidemia, defined as TG greater than 150 mg/dl (1.70 mmol/L), total cholesterol greater than 200 mg/dl (5.16 mmol/L), and/or LDL-cholesterol greater than 100 mg/dl (2.58 mmol/L). 4. willing to make return visits. 5. not currently receiving hormone replacement therapy or medications/pills containing hormones (such as hormonal contraception or hormone replacement therapy) in the past 12 months. 6. not currently taking berberine or nutraceuticals that contain berberine. 7. free of any congenital diseases, including familial hypercholesterolemia. 8. free of Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency. G6PD will be tested using G6PD rapid diagnostic tests. 9. free of hemolytic anemia. 10. free of any infectious diseases, e.g., seasonal influenza. 11. without liver/renal diseases. 12. not pregnant or planning to get pregnant in the next three months. Pregnancy will be ruled out using HCG ULTRA pregnancy tests. 13. not currently breastfeeding. Exclusion Criteria: * All men, and women who did not meet the aforementioned inclusion criteria and/or were unable or unwilling to provide consent.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental
berberine (500 mg orally twice a day)

Group II

Placebo
placebo (500 mg orally twice a day)

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

School of Public Health, The University of Hong Kong

Hong Kong, Hong KongOpen School of Public Health, The University of Hong Kong in Google Maps
Enrolling by invitationOne Study Center
Berberine's Effects on Lipids and Lipoproteins in Hyperlipidemic Chinese Women | PatLynk